258 related articles for article (PubMed ID: 2891720)
1. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
3. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
4. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
5. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long-acting somatostatin analogue SMS 201-995.
Barkan AL; Shenker Y; Grekin RJ; Vale WW
Cancer; 1988 Jan; 61(2):221-6. PubMed ID: 2891432
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analog treatment of acromegaly: new aspects.
Lamberts SW; del Pozo E
Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
[TBL] [Abstract][Full Text] [Related]
7. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
8. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995.
Ducasse MC; Tauber JP; Tourre A; Bonafe A; Babin T; Tauber MT; Harris AG; Bayard F
J Clin Endocrinol Metab; 1987 Nov; 65(5):1042-6. PubMed ID: 2889748
[TBL] [Abstract][Full Text] [Related]
9. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
10. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
11. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
Barkan AL; Beitins IZ; Kelch RP
J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
[TBL] [Abstract][Full Text] [Related]
12. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor.
Melmed S; Ziel FH; Braunstein GD; Downs T; Frohman LA
J Clin Endocrinol Metab; 1988 Aug; 67(2):395-9. PubMed ID: 2899089
[TBL] [Abstract][Full Text] [Related]
13. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
[TBL] [Abstract][Full Text] [Related]
14. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
16. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
[TBL] [Abstract][Full Text] [Related]
17. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly.
Pieters GF; Smals AE; Smals AG; von Gennep JA; Kloppenborg PW
Acta Endocrinol (Copenh); 1987 Apr; 114(4):537-42. PubMed ID: 2883797
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
19. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
20. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
Comi RJ; Gorden P
J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
